RxDoctor Payments Data

Morgan Hines

Medical · Redway, CANPI 1013482231

Payments from drug & device makers

$1,513in general payments, 2019–2025

Across 32 payments — averaging $47.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$310
  • Lilly USA, LLC$263
  • Novo Nordisk$242
  • Pfizer$160
  • Boston Scientific$150
  • Regeneron Healthcare Solutions, Inc.$122
  • plus $266 from 7 others

What the payments were for

  • Food & beverage$1,31987%
  • Education$19313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,513 in reported general payments places this provider in the 70th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$82,451
Medicare patients
487
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide37$541,221
IbrancePalbociclib26$433,040
NubeqaDarolutamide22$289,696
XtandiEnzalutamide20$161,016
OrgovyxRelugolix15$38,759
Abiraterone Acetate35$35,472
EliquisApixaban22$13,116
Anastrozole227$6,299
Letrozole76$2,221
Gabapentin142$1,995
Levothyroxine Sodium50$1,605
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen58$1,554
Tamoxifen Citrate53$1,354
Ibandronate Sodium22$1,060
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$160$446,15648 claims
BayerNubeqa$12$289,69622 claims
Lilly USA, LLCOlanzapine$263$47436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 medical providers in California.

Other medical in Redway

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →